Key facts
- It has raised $37.6M; the latest was Later Stage VC ($13.7M) in May 2025.
- Notable investors include Co-Power Capital Management, Galaxy Innovation Capital Management, Jintai Jinhong Investment, Kaitai Capital, Leo Group (Shanghai) — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for EndoCell (China)
- ·The full record, as it builds
Funding rounds
No funding rounds for EndoCell (China) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EndoCell (China)
Developer and provider of tissue and organ reconstruction technology for diabetes treatment. The company focuses on in vitro biofabrication of tissues and organs, committing to treating diabetes by islets transplantation.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Website
- endocell.cn/
- Ownership
- Privately Held (backing)
EndoCell (China) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EndoCell (China) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EndoCell (China) in its N-PORT filings yet. We sweep new filings monthly.